David Dai
Stock Analyst at UBS
(1.74)
# 3,350
Out of 5,055 analysts
30
Total ratings
34.62%
Success rate
-7.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Buy | $14 → $16 | $11.21 | +42.79% | 3 | Nov 14, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $103.09 | +13.49% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $16.62 | +128.64% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $96.50 | +36.79% | 3 | Oct 31, 2025 | |
| MRUS Merus | Downgrades: Neutral | $72 → $97 | $96.01 | +1.03% | 2 | Sep 30, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $9.33 | +114.36% | 1 | Sep 23, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $12.80 | +103.13% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $18.03 | +66.39% | 1 | Jul 1, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.47 | -19.03% | 2 | May 16, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $8.55 | +180.70% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $35.99 | -33.31% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.08 | +861.54% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $29.28 | +135.66% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $32.14 | +55.57% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $41.01 | +46.31% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.66 | +4,127.69% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $79.13 | -49.45% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.50 | +2,566.67% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.87 | +2,573.80% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $29.31 | +77.41% | 1 | Mar 17, 2020 |
Kura Oncology
Nov 14, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $11.21
Upside: +42.79%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $103.09
Upside: +13.49%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $16.62
Upside: +128.64%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $96.50
Upside: +36.79%
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $72 → $97
Current: $96.01
Upside: +1.03%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $9.33
Upside: +114.36%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $12.80
Upside: +103.13%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $18.03
Upside: +66.39%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.47
Upside: -19.03%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $8.55
Upside: +180.70%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $35.99
Upside: -33.31%
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $2.08
Upside: +861.54%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $29.28
Upside: +135.66%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $32.14
Upside: +55.57%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $41.01
Upside: +46.31%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.66
Upside: +4,127.69%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $79.13
Upside: -49.45%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.50
Upside: +2,566.67%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.87
Upside: +2,573.80%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $29.31
Upside: +77.41%